Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 25Terminated 10Withdrawn 6Active not recruiting 3Recruiting 2Unknown 1Not yet recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Other hematologic neoplasm 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 436Carboplatin 321Nivolumab 287Cyclophosphamide 280Specimen Handling 257Cisplatin 251Paclitaxel 248Magnetic Resonance Spectroscopy 248Radiotherapy 217Gemcitabine 180Dexamethasone 180Biopsy 177durvalumab 166atezolizumab 148Rituximab 138Lenalidomide 134Doxorubicin 134Docetaxel 130Bevacizumab 129Ipilimumab 125Radiation 118Capecitabine 117Pemetrexed 112Oxaliplatin 112Etoposide 111Radiosurgery 108Fluorouracil 108venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × alovudine × Clear all
NCT02392429 2026-05-28

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
87 enrolled 15 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01251874 2026-05-22

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
44 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02608216 2025-09-03

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

University of Pennsylvania

Phase 1 Active not recruiting
20 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡